A5084577356- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Pharmacogenetics and Drug Metabolism
- Acute Myocardial Infarction Research
- Pharmaceutical Practices and Patient Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Blood Coagulation and Thrombosis Mechanisms
- Pharmaceutical studies and practices
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Ischemic Stroke Management
- Hormonal Regulation and Hypertension
- Medication Adherence and Compliance
- Blood Pressure and Hypertension Studies
- Eicosanoids and Hypertension Pharmacology
- Cardiac Arrhythmias and Treatments
- Pharmaceutical Economics and Policy
- Hemoglobinopathies and Related Disorders
- Lipoproteins and Cardiovascular Health
- Iron Metabolism and Disorders
- Health Sciences Research and Education
- Pharmacovigilance and Adverse Drug Reactions
- Diagnosis and Treatment of Venous Diseases
- Pharmaceutical industry and healthcare
- Statistical Methods in Clinical Trials
University of Illinois Chicago
2016-2025
University of Illinois Urbana-Champaign
2005-2025
Illinois College
2007-2020
Loyola University Chicago
2020
University of Illinois Hospital & Health Sciences System
2012-2017
Indianapolis Zoo
2016
American College of Clinical Pharmacy
2013-2016
University of North Carolina at Pembroke
2016
University of Florida
2011-2014
IS practice
2002-2014
Objective To investigate pharmacokinetic and pharmacodynamic factors associated with population differences in warfarin doses needed to achieve anticoagulation, particular the possible involvement of genetic variability vitamin K epoxide reductase (VKOR) CYP2C9. Methods Warfarin maintenance dose, unbound plasma S-warfarin concentration [Cu(S)] INR were determined 157 Caucasians, 172 Japanese, 36 African-Americans stably anticoagulated patients. In a subset (n=166), fully carboxylated normal...
The objective of this study was to determine whether, in African-American patients, additional vitamin K oxidoreductase complex subunit 1 (VKORC1), cytochrome P450 2C9 (CYP2C9), CYP4F2, or apolipoprotein E (APOE) polymorphisms contribute variability the warfarin maintenance dose beyond what is attributable CYP2C9*2 and *3 alleles VKORC1 −1639G>A genotype. In a cohort 226 weekly requirements were lower those with CYP2C9*8 allele (34 (30–47) mg; P = 0.023) CYP2C9 *2, *3, *5, *6, *11 (33(28–40...
Recent clinical trial data cast doubt on the utility of genotype-guided warfarin dosing, specifically showing worse dosing with a pharmacogenetic versus algorithm in African Americans. However, many genotypes important Americans were not accounted for. We aimed to determine whether omission CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 alleles and rs12777823 G > A genotype affects performance algorithms Americans.In cohort 274 warfarin-treated Americans, we examined association between dose...
Objective: To provide recommendations, policies, and procedures pertaining to the provision of optimized anticoagulation therapy designed achieve desired clinical endpoints while minimizing risk anticoagulant-related adverse outcomes (principally bleeding thrombosis). Study Selection Data Extraction: Due this document's scope, medical literature was searched using a variety strategies. When possible, recommendations are supported by available evidence; however, because paper deals with...
The cytochrome P450 (CYP) 2C9 R150H (*8) allele occurs commonly in African Americans and is associated with lower warfarin dose requirements. We conducted a pharmacokinetic study to examine whether the CYP2C9*8 impacts clearance African-American patients. also an vitro kinetic of S-warfarin 7-hydroxylation using complementary DNA (cDNA)-expressed CYP2C9 enzymes. observed 30% reduction unbound oral 25% R- plasma concentration ratio patients (n = 12) as compared CYP2C9*1 homozygotes 26)....
Background Evidence of adherence and persistence patterns in anticoagulation ( AC ) therapy comparing treatment‐naïve non‐naïve patients is lacking. The objective this study was to evaluate medication a real‐world setting among ‐naïve ‐experienced with atrial fibrillation AF who were treated direct oral anticoagulants DOAC s). Methods newly initiating minimum 6 months continuous health plan enrollment pre postindex date (first prescription) identified from the Truven Health MarketScan...
With advancements in pharmacogenomics research and genotyping technology, implementation of into clinical practice is now feasible. The aim this publication to serve as a tutorial for institutions interested developing services. Topics covered include resources needed, decision support establishment, choosing platform, challenges faced with service implementation. This provides practical advice, drawing upon experience two established Clinical characteristics, such age, body weight, renal...
Study Objective To determine the procedural feasibility of a pharmacist‐led interdisciplinary service for providing genotype‐guided warfarin dosing hospitalized patients newly starting warfarin. Design Prospective observational study. Setting A 438‐bed tertiary care hospital affiliated with large academic institution. Patients Eighty who started therapy and were managed by implemented pharmacogenetics service. Intervention All received routine genotyping clinical consultation. Measurements...
Strategies to control the quality and cost of medication use are largely dependent on ability alter selection medications. Previous models prescribing behavior have focused physicians. In hospital setting, clinical pharmacists formulary committee members also key players in drug therapy decision-making. Differences between physicians, members, not been compared. Knowledge these differences could importance predicting effectiveness strategies designed influence this setting.To describe...
Background:Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is commonly treated with a low-molecular-weight heparin such as enoxaparin plus vitamin K antagonist (VKA) to prevent recurrence. Administration + VKA hampered by complexities laboratory monitoring frequent dose adjustments. Rivaroxaban, an orally administered anticoagulant, has been compared in the EINSTEIN trials. The objective was evaluate cost-effectiveness rivaroxaban...
In 2006, the American College of Clinical Pharmacy (ACCP) released a position statement and white paper to provide College's viewpoints on importance postgraduate pharmacy residency training as prerequisite for direct patient care practice vision that future clinical pharmacists engaged in would be certified by Board Specialties (BPS). Since release these papers, some members profession have interpreted ACCP's maintaining all pharmacists-regardless focus their professional activities-should...